Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC)

R. Figlin; C. Nicolette; N. Tannir; S.S. Tykodi; D. Chen; V. Master; B. Lane; M. Debenedette; T. Monesmith; W. Tan; S. Leland; C.G. Wood

Journal ArticleOPEN ACCESS

Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC)

Figlin R
Nicolette C
Tannir N
et al.

Annals of Oncology (2017) 28 v404

DOI: 10.1093/annonc/mdx376.003

N/ACitations

8Readers

Abstract

Methods: The Phase 3 ADAPT trial was designed to evaluate overall survival (OS) of rocapuldencel-T in combination (Combo) with standard-of-care (SOC) for the treatment of newly diagnosed mRCC as compared to SOC alone (Control). It included adults with synchronous, clear cell mRCC who were eligible for nephrectomy at 107 sites across North America, Europe and Israel.

Cite

CITATION STYLE

APA

Figlin, R., Nicolette, C., Tannir, N., Tykodi, S. S., Chen, D., Master, V., … Wood, C. G. (2017). Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC). Annals of Oncology, 28, v404. https://doi.org/10.1093/annonc/mdx376.003

Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC)

Abstract

Cite

Register to see more suggestions